The Growing Von Hippel-Lindau Disease Treatment Market is driven by Increasing Research and Development
Von Hippel-Lindau disease results from mutations in the VHL tumor suppressor gene which often leads to the development of various benign and malignant tumors. Currently available treatment options for Von Hippel-Lindau disease include surgery to remove tumors, radiation therapy, targeted drug therapy, and cryotherapy. Research is ongoing to develop more effective targeted drug therapies and genetic testing methods to detect mutations at an early stage.
The Von Hippel-Lindau Disease Market is estimated to be valued at USD 301.2 million in 2024 and is expected to reach USD 510.3 million by 2031, growing at a compound annual growth rate (CAGR) of 7.8% from 2024 to 2031.
As per various studies, approximately 1 in 36,000 people worldwide are reported to have Von Hippel-Lindau disease making it a rare genetic disorder. However, the increasing research activities to develop novel targeted therapies and diagnosis of the disease at an early stage are expected to boost the market growth during the forecast period.
Key players operating in the Von Hippel-Lindau disease treatment market are F. Hoffmann-La Roche Ltd, Novartis AG, Johnson & Johnson, Bristol-Myers Squibb, Pfizer Inc.
These players are focusing on conducting extensive research and clinical trials to develop more effective targeted drug therapies for treating Von Hippel-Lindau Disease Market tumors.
Get more insight on- Von Hippel-Lindau Disease Market
Get this Report in Japanese Language: フォン・ヒッペル・リンダウ病市場
Get this Report in Korean Language: 폰 히펠-린다우 질병 시장
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian